Georgios K. Vasileiadis

Georgios K. Vasileiadis

Auto-generated profile, based on publicly available information

Georgios K. Vasileiadis

Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University General Hospital of Larissa, University of Thessaly, Biopolis, 40500, Larissa, Greece

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2018 in Autoimmunity Highlights
Verified
Journal Article
Open access
PDF file
GVGeorgios K. Vasileiadis
Georgios K. Vasileiadis
Dardiotis EfthimiosDardiotis Efthimios
Dardiotis Efthimios
AMAthanasios Mavropoulos
Athanasios Mavropoulos
ZTZisis Tsouris
Zisis Tsouris
VTVana Tsimourtou
Vana Tsimourtou
GHGeorgios M. Hadjigeorgiou
Georgios M. Hadjigeorgiou
Current clinical experience with immunomodulatory agents and monoclonal antibodies in principle has established the benefit of depleting lymphocytic populations in relapsing–remitting multiple sclerosis (RRMS). B and T cells may exert multiple pro-inflammatory actions, but also possess regulatory functions making their role in RRMS pathogenesis much more complex. There is no clear correlation of Tregs and Bregs with clinical features of the disease. Herein, we discuss the emerging data on regulatory T and B cell subset distributions in MS and their roles in the pathophysiology of MS and its murine model, experimental autoimmune encephalomyelitis (EAE). In addition, we summarize the immunomodulatory properties of certain MS therapeutic agents through their effect on such regulatory cell subsets and their relevance to clinical outcomes.

9 August 2019 in Immunologic Research
Verified
Journal Article
Closed access
GNGeorgios Ntolkeras
Georgios Ntolkeras
CBChrysanthi Barba
Chrysanthi Barba
AMAthanasios Mavropoulos
Athanasios Mavropoulos
GVGeorgios K. Vasileiadis
Georgios K. Vasileiadis
Dardiotis EfthimiosDardiotis Efthimios
Dardiotis Efthimios
Bogdanos DimitriosBogdanos Dimitrios
Bogdanos Dimitrios

18 June 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
BBBeatrice Bergström
Beatrice Bergström
CLChristina Lundqvist
Christina Lundqvist
GVGeorgios K. Vasileiadis
Georgios K. Vasileiadis
HCHans Carlsten
Hans Carlsten
OEOlov Ekwall
Olov Ekwall
AEAnna-Karin H. Ekwall
Anna-Karin H. Ekwall
The autoimmune regulator AIRE controls the negative selection of self-reactive T-cells as well as the induction of regulatory T-cells in the thymus by mastering the transcription and presentation of tissue restricted antigens (TRAs) in thymic cells. However, extrathymic AIRE expression of hitherto unknown clinical significance has also been reported. Genetic polymorphisms of AIRE have been associated with rheumatoid arthritis (RA), but no specific disease-mediating mechanism has been identified. Rheumatoid arthritis is characterized by a systemic immune activation and arthritis. Activated fibroblast-like synoviocytes (FLS) are key effector cells, mediating persistent inflammation, and destruction of joints. In this study, we identified AIRE as a cytokine-induced RA risk gene in RA FLS and explored its role in these pathogenic stroma cells. Using RNA interference and RNA sequencing we show that AIRE does not induce TRAs in FLS, but augments the pro-inflammatory response induced by tumor necrosis factor and interleukin-1β by promoting the transcription of a set of genes associated with systemic autoimmune disease and annotated as interferon-γ regulated genes. In particular, AIRE promoted the production and secretion of a set of chemokines, amongst them CXCL10, which have been associated with disease activity in RA. Finally, we demonstrate that AIRE is expressed in podoplanin positive FLS in the lining layer of synovial tissue from RA patients. These findings support a novel pro-inflammatory role of AIRE at peripheral inflammatory sites and provide a potential pathological mechanism for its association with RA.